X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs CADILA HEALTHCARE - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD CADILA HEALTHCARE LUPIN LTD/
CADILA HEALTHCARE
 
P/E (TTM) x 19.9 32.1 62.0% View Chart
P/BV x 2.7 6.0 45.2% View Chart
Dividend Yield % 0.9 0.8 117.9%  

Financials

 LUPIN LTD   CADILA HEALTHCARE
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
CADILA HEALTHCARE
Mar-17
LUPIN LTD/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,750460 380.4%   
Low Rs1,384305 453.6%   
Sales per share (Unadj.) Rs387.492.1 420.6%  
Earnings per share (Unadj.) Rs56.614.8 382.2%  
Cash flow per share (Unadj.) Rs76.818.5 415.8%  
Dividends per share (Unadj.) Rs7.503.20 234.4%  
Dividend yield (eoy) %0.50.8 57.2%  
Book value per share (Unadj.) Rs298.968.0 439.6%  
Shares outstanding (eoy) m451.581,023.74 44.1%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x4.04.2 97.4%   
Avg P/E ratio x27.725.8 107.2%  
P/CF ratio (eoy) x20.420.7 98.5%  
Price / Book Value ratio x5.25.6 93.2%  
Dividend payout %13.221.6 61.3%   
Avg Mkt Cap Rs m707,513391,581 180.7%   
No. of employees `00016.816.9 99.6%   
Total wages/salary Rs m28,49515,002 189.9%   
Avg. sales/employee Rs Th10,418.35,594.5 186.2%   
Avg. wages/employee Rs Th1,697.0890.1 190.7%   
Avg. net profit/employee Rs Th1,523.0899.9 169.2%   
INCOME DATA
Net Sales Rs m174,94394,295 185.5%  
Other income Rs m1,0651,286 82.8%   
Total revenues Rs m176,00895,581 184.1%   
Gross profit Rs m44,93119,036 236.0%  
Depreciation Rs m9,1223,750 243.3%   
Interest Rs m1,525450 339.0%   
Profit before tax Rs m35,34916,122 219.3%   
Minority Interest Rs m-72338 -21.2%   
Prior Period Items Rs m830-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m9,7851,289 759.1%   
Profit after tax Rs m25,57515,168 168.6%  
Gross profit margin %25.720.2 127.2%  
Effective tax rate %27.78.0 346.2%   
Net profit margin %14.616.1 90.9%  
BALANCE SHEET DATA
Current assets Rs m119,54260,223 198.5%   
Current liabilities Rs m61,20653,058 115.4%   
Net working cap to sales %33.37.6 438.8%  
Current ratio x2.01.1 172.1%  
Inventory Days Days7670 108.8%  
Debtors Days Days9088 101.9%  
Net fixed assets Rs m131,66072,984 180.4%   
Share capital Rs m9031,024 88.2%   
"Free" reserves Rs m134,07368,576 195.5%   
Net worth Rs m134,97669,600 193.9%   
Long term debt Rs m56,47824,684 228.8%   
Total assets Rs m266,073152,207 174.8%  
Interest coverage x24.236.8 65.6%   
Debt to equity ratio x0.40.4 118.0%  
Sales to assets ratio x0.70.6 106.1%   
Return on assets %10.210.3 99.3%  
Return on equity %18.921.8 86.9%  
Return on capital %19.317.9 107.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m81,88521,280 384.8%   
Fx outflow Rs m21,50610,874 197.8%   
Net fx Rs m60,37810,406 580.2%   
CASH FLOW
From Operations Rs m41,14813,495 304.9%  
From Investments Rs m-25,287-29,103 86.9%  
From Financial Activity Rs m4,33223,158 18.7%  
Net Cashflow Rs m20,1937,556 267.2%  

Share Holding

Indian Promoters % 46.6 74.8 62.3%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 8.3 136.1%  
FIIs % 31.9 5.9 540.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 11.0 91.8%  
Shareholders   98,259 44,069 223.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  DR. REDDYS LAB  

Compare LUPIN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - JUBILANT LIFE SCIENCES COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS